Abstract
This report includes defined and up to date development strategies for 176
lymphoma therapeutic drugs (>230 projects) within the portfolio of 106
investigators, from Ceased to Marketed. In total the report assesses five
different sub-indications of lymphoma (B-cell lymphoma, Hodgkin' s lymphoma,
non-Hodgkin' s lymphoma, T-cell lymphoma and Lymphoma (general)). The report is
written for you to understand and assess the impact of competitor entry and
corresponding changes to development strategies for your own portfolio
products. It serves as an external commercial advocate for pharmaceutical
companies' portfolio planning and new product planning by:
Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
Assisting you to make informed decisions in selecting lymphoma sub-indications
that are known to be appropriate for your drug' s properties
Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report will also be an important part of creating and implementing a
market development plan for any lymphoma therapeutic drug to ensure that the
optimal market conditions exist by the time the product is commercialized.
| 
View Cart
